FindTrial
Sign In

The principle of hemostasis complementarity and study on the efficacy and safety of non-blood product medicine-xueyou mixture in treating hemophlilia

The principle of hemostasis complementarity and study on the efficacy and safety of non-blood product medicine-xueyou mixture in treating hemophlilia

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPN-16008549
Enrollment
Unknown
Registered
2016-05-27
Start date
2016-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemophilia

Interventions

Test group:Using Hemostasis Mixture
Control group:Using FVIII /FIX factor

Sponsors

Shaanxi Yida Hemophilia Institute affiliated Xi’an Xincheng Yida Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 85 Years

Inclusion criteria

Inclusion criteria: Test group: 1. Meet the clinical-defined hemophilia criteria; 2. Agree using non-blood product medicine - Hemostasis Mixture to treat hemophlia and disuse FVIII /FIX during the experiment; 3. sign informed conset. Control group: 1. Meet the clinical-defined hemophilia criteria; 2. Agree to use recombinant coagulation factor during the experiment; 3. sign informed conset.

Exclusion criteria

Exclusion criteria: 1. Patients with hemorrhagic disease of non-hemophlia such as von willebrand disease and secondary recombinant FVIII /FIX deficiency; 2. Patients with mortal danger; 3. Drug allergies; 4. Incomplete personal information.

Design outcomes

Primary

MeasureTime frame
Hemostasis effective time;Hematoma absorption time;Effective rate of hemostasis,death rate,disability rate,the usege of FVIII /FIX;—

Countries

China

Contacts

Public ContactLiu Shanxi

Shaanxi Yida Hemophilia Institute affiliated Xi’an Xincheng Yida Hospital

13992821100@139.com+86 15091331100

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026